Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8.

@article{Curfman2005ExpressionOC,
  title={Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8.},
  author={Gregory Curfman and Stephen Morrissey and Jeffrey M. Drazen},
  journal={The New England journal of medicine},
  year={2005},
  volume={353 26},
  pages={
          2813-4
        }
}
Drs. Gregory Curfman, Stephen Morrissey, and Jeffrey Drazen report on recently obtained information regarding inaccuracies in data in the report of the Vioxx Gastrointestinal Outcomes Research study that raises concern about certain conclusions in the article. 

Tables from this paper

Expression of concern reaffirmed.
TLDR
Evidence that the VIGOR article did not accurately represent the safety data available to the authors when the article was being reviewed for publication is highlighted.
4 years after withdrawal of rofecoxib: where do we stand today?
TLDR
It cannot be excluded that non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs) may be associated with a small increase in the absolute risk for thrombotic events, and the entire substance group of NSAIDs may have cardiovascular side effects but to different degrees.
Conflicts of interest and disclosures in publications.
Peptic ulcer disease
  • J. Louw
  • Medicine, Biology
    Current opinion in gastroenterology
  • 2006
Purpose of review This review attempts to contextualize some of the clinically important publications of the last 2 years as they relate to the broad topic of dyspepsia and peptic ulcer disease, both
Unbalanced reporting of benefits and harms in abstracts on rofecoxib
TLDR
The reporting of benefits and harms was not balanced and changed markedly over time, but knowledge of increased risk of thrombosis existed early on, but the harms came into focus too late, when the drug was already withdrawn, and when tens of thousands of patients had been harmed unnecessarily.
Cerebrovascular Events After Discontinuation of Rofecoxib Treatment
TLDR
The finding of an excess of thrombotic cardiovascular events, primarily of myocardial infarction, in the VIGOR trial raised concern about the cardiovascular safety of rofecoxib, and also of COX-2 inhibitors in general.
Inconsistencies in Cardiovascular Data from COX-2 Inhibitor Trials–is it a Class Effect?
TLDR
Concerns previously expressed regarding the selective and partial reporting of the gastrointestinal side effects from the CLASS study are added and it is reported that the published CLASS study differs from the original protocol in primary outcomes, statistical analysis, trial duration and conclusions.
Drugs and trials: lessons from Plato.
Practice Advisory on the Appropriate Use of NSAIDs in Primary Care
TLDR
Consensus statements and associated guidance regarding appropriate NSAID use based on a review of current evidence by a multidisciplinary group of expert clinicians are presented to guide primary care practitioners within Asia in the appropriate use of NSAIDs in primary care.
The Vioxx® legacy: Enduring lessons from the not so distant past.
TLDR
While it is no longer making its way into prescription bottles, rofecoxib's legacy lives on, in its enduring influences, on drug safety monitoring in the conduct of randomized controlled trials (RCTs) and on modern practices in drug marketing and development.
...
1
2
3
4
5
...

References

COMPARISON OF UPPER GASTROINTESTINAL TOXICITY OF ROFECOXIB AND NAPROXEN IN PATIENTS WITH RHEUMATOID ARTHRITIS
TLDR
In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.